Electromed (NSDQ:ELMD) today released results from an independent clinical study exploring the use of high frequency chest wall oscillation therapy with its SmartVest, touting that it significantly reduced severe exacerbations and hospitalizations for non-cystic fibrosis bronchiectasis patients.
Findings from the study were presented at the World Bronchiectasis Conference in Washington D.C., the New Prague, Minn.-based company said.
“Preventing exacerbations and maintaining pulmonary function is vital to the health and well-being of bronchiectasis patients. This independent study builds on previously published evidence and clearly demonstrates that bronchiectasis patients can achieve significantly better outcomes with the initiation of SmartVest therapy,” regulatory and clinical affairs director Chet Sievert said in a prepared statement.
The study was the first to report that HFCWO use resulted in “stabilization of key lung function parameters,” which the company said supports that early bronchiectasis treatment with the SmartVest could significantly slow normal progression of the disease.
“We are thrilled not only by the results of this study, but the significant milestone it represents. This is the first independent study to evaluate bronchiectasis-related exacerbations using HFCWO therapy. The results confirm what we’ve said all along: incorporating the SmartVest into bronchiectasis treatment significantly reduces exacerbations and improves patient outcomes,” CEO Kathleen Skarvan said in a press release.
In May, Electromed said that the Internal Revenue Service would refund approximately $406,000 the company paid related to the federal medical device excise taxes associated with the sale of its SmartVest airway clearance system.